Lomitapide—a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia

Claudia Stefanutti

Published online: 18 June 2020
© The Author(s) 2020, corrected publication 2020

Abstract

Purpose of Review Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic condition characterized by high levels of Low density lipoprotein cholesterol (LDL-C); overt, early-onset atherosclerotic cardiovascular disease (ASCVD); and premature cardiovascular events and mortality. Lomitapide is a first-in-class microsomal triglyceride transfer protein inhibitor for the treatment of HoFH. This review provides an update on data emerging from real-world studies of lomitapide following on from its pivotal phase 3 clinical trial in HoFH.

Recent Findings Recent registry data have confirmed that HoFH is characterized by delayed diagnosis, with many patients not receiving effective therapy until they are approaching the age when major adverse cardiovascular events may occur. Data from case series of varying sizes, and from a 163-patient registry of HoFH patients receiving lomitapide, have demonstrated that lomitapide doses are lower and adverse events less severe than in the phase 3 study. Lomitapide enables many patients to reach European Atherosclerosis Society LDL-C targets. Some patients are able to reduce frequency of lipoprotein apheresis or, in some cases, stop the procedure altogether—unless there is significant elevation of lipoprotein (a). Modelling analyses based on historical and clinical trial data indicate that lomitapide has the potential to improve cardiovascular outcomes and survival in HoFH.

Summary Real-world clinical experience with lomitapide has shown the drug to be effective with manageable, less marked adverse events than in formal clinical studies. Event modelling data suggest a survival benefit with lomitapide in HoFH.

Keywords Homozygous familial hypercholesterolemia · Lomitapide · Cardiovascular disease · Lipoprotein apheresis · Drug therapy

Homozygous Familial Hypercholesterolemia

Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic disorder of lipid metabolism that results in high LDL-C levels with or without concomitant elevation in lipoprotein (a) (Lp(a)) at a very early age [1, 2]. Patients with HoFH have extremely high LDL-C levels from birth, and this is associated with early-onset atherosclerotic cardiovascular disease (ASCVD) and aortic supra-aortic valve disease. This, in turn, causes a range of associated life-threatening cardiac conditions [1]. If left untreated, HoFH is associated with ASCVD at a mean age of 12.5 years, with mean survival just 18 years [3].

The prevalence of HoFH is estimated to be 1:300,000 people [4], with founder effects evident in some populations with low levels of genetic admixture or high incidence of consanguineous marriages [5, 6]. The condition arises when an individual inherits two mutations that encode defects in proteins involved in the catabolism of LDL-C. Affected genes can include LDLR, LDLRAP1, APOB, and PCSK9 [1]. The pattern of mutations is extremely varied, whereby patients may have a pair of matching mutations (“true” or “simple” homozygotes), a pair of unmatched mutations in the same allele (compound heterozygotes), or two unmatched mutations in two different alleles (double heterozygotes) [1]. Within these mutation patterns, there is further variability. LDL receptor

This article is part of the Topical Collection on Nonstatin Drugs
(LDL-R), LDL receptor adapter protein 1 (LDLRAP1), and apolipoprotein B (ApoB) are responsible for clearing LDL-C from plasma, while proprotein convertase subtilisin/kexin type 9 (PCSK9) is responsible for inhibiting the recycling LDL-R to the cell surface by targeting the LDL-R for lysosomal degradation. Therefore, LDL-C levels will be elevated by loss-of-function mutations in LDLR, LDLRAP1, and APOB and by gain-of-function mutations in PCSK9 [1]. The severity of the mutations results in wide phenotypic variability, whereby affected proteins can be completely or partially disabled [1].

Long-Term Risks of HoFH—Data from Registries

Long-term analysis of groups of patients with HoFH has been conducted in the HoFH International Clinical Collaborators (HICC) registry, the Turkish A-HIT 1 registry, and the Lomitapide Observational Worldwide Evaluation Registry (LOWER). The 2018 data from the HICC registry has found that among 220 patients analyzed, mean (± SD) age at first myocardial infarction or aortic valve replacement was 35.7 ± 8.3 years, with patients as young as 17 years experiencing these events. Mean age of death was 42.4 ± 19.5 years (lower limit 13 years) most deaths (67%) were of cardiovascular origin [7]. The Turkish A-HIT 1 registry of HoFH patients undergoing lipoprotein apheresis (LA) to control their condition evaluated 88 patients and found that mean age of diagnosis was delayed to 12 ± 11 years [8], which is only 5 years before the HICC registry suggests that serious cardiovascular (CV) events may occur [7]. These registry data serve to illustrate the need to diagnose HoFH early in the life of the patient and to apply effective treatments with the greatest urgency. Individual CV profiles ought to be carefully assessed in all patients regardless of age.

Standards of Care

HoFH is extremely difficult to treat and requires inventive therapeutic solutions. For patients with common, polygenic causes of elevated cholesterol, the standard of care for lipid lowering is statins with or without ezetimibe. Statins work by inhibiting β-hydroxy β-methylglutaryl-CoA (HMG CoA), and one of the chief results of this is the increased expression of LDL-R via sterol regulatory element-binding protein (SREBPs) [9]. This activity requires that the LDL-R is functional, even if only partially. In patients with HoFH with little residual LDL-R activity (e.g., <2%), statins are only able to reduce LDL-C levels by a modest amount (10–25%), even with maximal doses [1, 3, 10]. Other patients with less severe mutations may respond in part to statins.

For many years, a mainstay of therapy in HoFH has been LA. LA involves the extracorporeal removal of cholesterol and can reduce LDL-C levels by more than 50% and delay and interrupt the onset of ASCVD [11–13]. However, LDL-C levels rebound to baseline within 2 weeks of an LA procedure [14]. This means that patients using LA to control LDL-C levels require frequent sessions to avoid extended periods of elevated LDL-C levels, which exposes them to long-term risks of early-onset ASCVD [15]. For many patients, LA needs to be applied weekly to maintain interval LDL-C levels below European Atherosclerosis Society (EAS) targets. However, LA is undoubtedly a burden on time, education, and work. Attendance at treatment centers can be problematic, and LA is not universally available in all countries and regions [16, 17].

On the other hand, LA has been demonstrated to improve life expectancy and delay morbidity associated with ASCVD. This was shown in the recent Sino-Roman Study in which Italian HoFH patients receiving lipid-lowering therapies (LLTs), including lomitapide, plus LA had significantly greater survival and less incidence of (CVD) compared with Chinese HoFH patients who received standard LLTs but neither LA nor lomitapide (Table 1) [18*]. Importantly, LA has the capability to reduce levels of Lp(a) [19], and the Sino-Roman study showed that elevated levels of Lp(a) is associated with increased mortality in HoFH [18*]. Therefore, LA has the potential to improve survival via removal of lipid species that are refractory to pharmacological therapy. LA also has a range of pleiotropic benefits including downregulation of pro-inflammatory mediators, possibly via alterations in transcription of cytokine mRNA [19]. Moreover, LA induces hemodynamic and hemorheological effects at any arterial district, including coronary arteries, thereby improving myocardial perfusion [20].

In common with statins, the recently developed PCSK9 inhibitors, which work by enhancing the cellular recycling of LDL-R, also require residual LDL-R function to reduce plasma LDL-C levels [21]. The difficulties in using PCSK9 inhibitors in all patients with HoFH were borne out by results from the TESLA and TAUSSIG trials, which demonstrated that the PCSK9 inhibitor evolocumab had diminished activity in HoFH patients with negative functional mutations versus those with mutations allowing some residual LDL-R activity [22, 23]. Among all the HoFH patients in the TESLA trial, response was highly variable, whereby evolocumab reduced LDL-C by approximately 20%, but with a standard deviation of 24% [22]. In the TAUSSIG trial, responses were similarly variable and an analysis by mutation type revealed consistently poor responses in HoFH patients with null LDLR mutations [23]. Long-term data from TAUSSIG suggests a mean response rate of evolocumab in FH of 21.2% [24]. The issues with variability of response to PCSK9 inhibitors in HoFH indicate a need to carefully select therapies based on available genetic profiling [25]. Expert opinion underscores the limitations of PCSK9 inhibitors in HoFH and suggests that they
may not have the broad applicability required to reduce the burden of LA, certainly for HoFH patients with receptor-negative mutations [26].

Given the problems associated with statin- and PCSK9-based therapy in HoFH, other treatment modalities have been sought, including an anti-sense oligonucleotide that targets mRNA for ApoB [27] (now discontinued) and lomitapide.

**Lomitapide**

Lomitapide is an oral microsomal triglyceride transfer protein inhibitor that prevents assembly of apolipoprotein-containing lipoproteins in the liver and intestines [28]. The drug works by binding directly to microsomal triglyceride transfer protein (MTP) in the endoplasmic reticulum of hepatocytes and enterocytes, which inhibits the assembly of very low-density lipoprotein (VLDL) and chylomicrons [28, 29]. MTP is responsible for the modulation of the number of apolipoprotein-containing particles that are released into the blood, and interestingly, rare, recessive mutations in MTP lead to abetalipoproteinemia, which is characterized by ultralow levels of plasma cholesterol and complete absence of plasma LDL-C and apoB [29, 30].

Lomitapide is licensed as an adjunct to a low-fat diet (<20% energy from fat) and other lipid-lowering medicinal products with or without LA in adult patients with HoFH. The introduction of lomitapide has provided an additional option to tailor LLT in HoFH to deliver the therapeutic intensity required in HoFH to mitigate the risk of ASCVD. Patients receiving lomitapide should take daily oral dietary supplements that provide 400 IU vitamin E and approximately 200 mg linoleic acid, 110 mg eicosapentaenoic acid, 210 mg alpha linolenic acid, and 80 mg docosahexaenoic acid per day.

**Clinical Trials**

In an open-label phase 3 trial of lomitapide in adult patients with HoFH (NCT00730236), lomitapide was dosed according to a predefined dose-escalation schedule [28].

| Variable | Italy (n = 18) | China (n = 44) | P value |
|----------|---------------|---------------|---------|
| Age started pharmacotherapy treatment (years) | 5.6 ± 3.4 | 10.7 ± 4.6 | < 0.001 |
| Lipid-lowering drugs (%) | 94.4 | 95.5 | 0.866 |
| Statins (%) | 88.9 | 95.5 | 0.339 |
| Ezetimibe (%) | 77.8 | 81.8 | 0.715 |
| Resins (%) | 66.7 | 0 | < 0.001 |
| Fibrates (%) | 16.7 | 0 | 0.022 |
| Probucol (%) | 0 | 77.3 | < 0.001 |
| PCSK9 inhibitors (%) | 0 | 0 | – |
| Lomitapide (%) | 61.1 | 0 | < 0.001 |
| Age started lomitapide (years) | 23.5 ± 4.1 | – | – |
| Lipoprotein apheresis (%) | 100 | 0 | < 0.001 |
| Age started apheresis (years) | 8.9 ± 5.5 | – | – |
| Treated LDL cholesterol (mmol/L) | 6.6 ± 2.7* | 13.1 ± 2.7 | < 0.001 |
| ΔLDL cholesterol (mmol/L) | 12.5 ± 5.0 | 2.6 ± 3.6 | < 0.001 |
| Treatment duration (years) | 17.4 ± 8.8 | 5.5 ± 4.8 | < 0.001 |
| LDL cholesterol life (years)† | 258.9 ± 98.7 | 227.3 ± 112.8 | 0.305 |
| Mean LDL cholesterol exposure/year (mmol/L)‡ | 12.4 ± 3.0 | 14.6 ± 3.0 | 0.011 |
| CVD event, n (%) | 4 (22.2) | 20 (45.5) | 0.088 |
| Age at CVD event (years) | 19.0 ± 9.6 | 16.1 ± 5.8 | 0.421 |
| Death, n (%) | 3 (16.7) | 14 (31.8) | 0.225 |
| Age at death (years) | 20.3 ± 10.7 | 17.9 ± 6.2 | 0.586 |

Continuous variables are expressed as mean ± standard deviation, and categorical variables are expressed as proportions (Permission will be needed from Elsevier to reproduce this.)

CVD cardiovascular disease, LDL low-density lipoprotein, PCSK9 proprotein convertase subtilisin/kexin type 9

*Time-average LDL cholesterol calculated using Kroon’s equation [14]
†Censored at age 30 years
‡Adjusted for (baseline) untreated LDL cholesterol
to an escalation to maximum-tolerated dose. All patients were advised to follow a diet in which < 20% of energy was derived from fat. Background LLTs were maintained, and this included LA for 18 of the 29 enrolled individuals. Over 26 weeks, lomitapide resulted in median reductions in plasma LDL-C of 50%. ApoB levels were reduced by 49% [31]. These results were largely maintained out to the planned 78 weeks of the pivotal trial. LDL-C levels in the 23 patients remaining at week 78 were 38% lower than baseline [31]. Given the mode of action of lomitapide, it was not surprising that the most predominant adverse events were gastrointestinal in nature. Elevations in liver function test (LFTs) > 5× ULN occurred in four patients, but these resolved with temporarily interruption of lomitapide [31]. On the basis of the results of this study, lomitapide was licensed for use as an adjunct to low-fat diet in adult patients with HoFH in the USA and Europe and areas of North America, Latin America, and Asia.

Patients who completed the 78-week pivotal phase 3 study were eligible to enroll in an extension phase (NCT00943306) in which lomitapide was administered for a total of 294 weeks. Nineteen patients enrolled in this phase [32]. At week 246 of the extension phase of the phase 3 trial, 14 (74%) and 11 (58%) of the 19 remaining patients reached LDL-C targets of 100 mg/dL and 70 mg/dL, respectively, at least once during the study period [32]. The extension phase revealed information about the long-term adverse event profile of lomitapide. In common with the phase 3 study, most adverse events were gastrointestinal, commensurate with the mode of action of the drug. The most frequently reported events were diarrhea, nausea, dyspepsia, and vomiting [32]. Twenty-one percent of patients experienced liver function test (LFT) excursions ≥ 5× upper limit of normal, but these were usually associated with coexistent use of cytochrome P450 3A4 inhibitors or excess alcohol. In all cases, elevated LFTs were managed with a temporary dose decrease or interruption in lomitapide [32].

Both the phase 3 trial and the extension phase revealed elevations in hepatic fat in patients taking lomitapide; however, this has not been associated with elevated LFTs in all patients, and no overt liver disease has been attributable to lomitapide therapy. Nevertheless, lomitapide has been subject to a Risk Management Plan (RMP) to monitor long-term effects of lomitapide on the liver [32]. In common with general findings that adverse events to lomitapide regress over time, the incidence of drug-related adverse events in the extension phase of the lomitapide phase 3 trial was lower than that in the earlier core study (84.2% versus 42.1%) [32].

A further phase 3 study was conducted in Japan (NCT02173158) in which nine adult HoFH patients were administered lomitapide over the course of a core 26-week period and a subsequent 30-week follow-up [33]. LLT and dose escalation were conducted according to the phase 3 pivotal trial. Reductions in mean LDL-C levels were similar to those in the pivotal phase 3 trial (42%). In common with the phase 3 trial, some patients were able to increase their LA intervals while maintaining reductions in plasma LDL-C. Six patients were able to achieve LDL-C < 100 mg/dL at least once during the efficacy phase [33]. Adverse events mirrored those of the pivotal trial [33]. The Japanese trial also had an extension phase that enrolled five of the eight patients who completed the core study [34]. A mean 35.6% reduction in LDL-C levels was observed between the end of the 26-week efficacy phase of the core study and 60 weeks of follow-up in the extension study. Two of the patients achieved LDL-C levels < 100 mg/dL. Adverse events were similar to the core study [34].

The overall picture from the clinical trials of lomitapide is that the drug is effective in lowering LDL-C and that many patients can achieve levels < 100 mg/dL. This occurs regardless of the application of LA, and LA intervals can be extended in patients receiving the drug—however, it should be borne in mind that LA has other effects such as reduction in Lp(a) levels and modulation of inflammatory mediators [35] that have not been recorded for lomitapide. Adverse events associated with lomitapide are chiefly gastrointestinal and relatively straightforward to manage.

**Real-World Evidence**

In rare diseases, such as HoFH, there is an ongoing problem of data availability and clinical trial size. In contrast with other, more common diseases, clinical trials of orphan drugs in rare disease are smaller due to the size of the available pool of patients. Additionally, once a drug for a rare disease is in general clinical use, large bodies of “real-world” evidence (RWE) or “big data,” as it is often known, will never become available. This makes it extremely difficult to conduct analyses such as median time of survival.

In addition to the limitations of formal data availability, for lomitapide, there is an additional technical aspect of the clinical trial that means that the drug is used differently in the clinic than in the phase study. In the phase 3 study, lomitapide was dosed according to a maximum-tolerated dosing regimen [31]. In this schema, patients undergo dose escalation until an adverse event occurs that requires dose titration. In contrast, in the clinic, patients undergo dose escalation only until desired efficacy is reached. For lomitapide, this means that the doses seen in reports of real-world use of the drug are lower than that in the clinical trial [36]. Lower doses have the potential to drive down the incidence of adverse events.

RWE on lomitapide has become available both from patient case reports and from registry data (Fig. 1). One of the largest case series evaluated outside of a clinical trial setting was that of an Italian cohort of 15 adults with HoFH. Importantly, ten of the patients had mutations in LDLR, and five had autosomal recessive hypercholesterolemia (ARH) [36]. ARH is a rare autosomal recessive form of HoFH. It is caused by mutations in LDLRAP1, which codes for the low-
density lipoprotein receptor adaptor protein-1. This protein plays a key role in the internalization of the LDL-R/LDL-C receptor complex, and loss-of-function mutations in the gene result in LDL-C remaining in circulation rather than being internalized by hepatocytes [37–40].

In the Italian study, HoFH patients, including five with ARH, were treated with lomitapide for more than 6 months, along with standard LLTs. LA was conducted in 10 of the patients. Mean LDL-C levels decreased by 68%, and this was achieved with a mean lomitapide dose of 19 mg/day [36]. This contrasts sharply with the median dose of 40 mg/day in the pivotal phase 3 trial [31]. On this lower dose, none of the patients discontinued lomitapide, and there were no problematic elevations in LFTs [36]. A subset of patients were monitored with liver ultrasound ($n=5$) or magnetic resonance imaging (MRI) ($n=1$). However, this was not conducted in a comprehensive manner, so conclusions on hepatic steatosis cannot be reliably determined [36].

A follow-up study was conducted by the same group in Italy, whereby electronic case reports from 52 patients with ARH were examined. Mean follow-up was 14.1 ± 7.3 years. Among the patients, high doses of statins and ezetimibe were recorded, and just over half of the patients were receiving apheresis. Six of the patients (11.5%) had received lomitapide [37]. Compared with other lipid lowering medication, patients receiving lomitapide had the greatest decreases in LDL-C levels, despite two of the patients stopping LA. LDL-C levels were reduced by 88.3 ± 5.0 mg/dL compared with 62.0 ± 22.5% for statins plus ezetimibe and 70.6 ± 10.3% for the same regimen with LA added. The research group commented that the use of lomitapide in ARH warrants further attention [37].

Staying with Italy, Stefanutti et al. described seven cases of genetically determined HoFH treated with lomitapide in a general clinic setting in Rome [41]. Following dose titrations, lomitapide doses were in the range 10–30 mg/day for five of the patients. One patient received a higher dose at 60 mg/day, and another patient was on just 5 mg/day. Three of the patients achieved LDL-C reductions of > 50%. The patient on the very low lomitapide dose did not experience appreciable decreases in LDL-C. Gastrointestinal adverse events were managed by adjustments to intake of dietary fat [41]. An Italian cardiology unit also identified two HoFH cases by applying clinical criteria followed by genetic confirmation of homozygosity [42]. One of these patients achieved a 78% reduction in LDL-C to 66 mg/dL on lomitapide 20 mg/day. The other patient achieved a 60% reduction to 107 mg/dL on just 5 mg/day with background statins and ezetimibe [42]. In both patients, hepatic ultrasound showed healthy livers without steatosis or fibrosis [42].

While hepatic steatosis is also common with lomitapide, and the long-term implications of this remain unclear, there are follow-up data from the Roman Stefanutti group that indicate that steatosis can persist in patients receiving the drug. In the Roman cohort, steatosis was determined with a combination of ultrasound and MRI. In two patients, diffuse and/or slight hepatic steatosis was evident in up to 8 years of follow-up (Table 2). MRI from patient 3 is pictured in Fig. 2 and shows no evidence of steatosis at follow-up. In contrast, the ultrasound from patient 4 (this patient could not have an MRI due to a replacement aortic valve.) shows evidence of slight steatosis 3 years after commencement of lomitapide (Fig. 3). Slight steatosis that was evident in patient 2 also appears to have persisted, but the imaging technique for this patient was changed between 2016 and 2019. In the Rome clinic, patients are routinely followed up with MRI and ultrasound depending on the evolution of liver abnormalities in patients receiving lomitapide as this is considered to be important while we continue to gather information on the long-term impact of the drug on the liver.

Elsewhere, a small number of case series of different sizes have been published. A 4-patient, multinational case series was published by Roeters van Lennep et al., who observed LDL-C reduction with lomitapide in the range 35–83%. The patients were receiving a range of background LLT, but one patient was treated with lomitapide alone [43]. A larger
patient series from a Greek group followed 12 HoFH patients for 3–24 months (median 13.8 ± 7.9) of lomitapide therapy [44]. The patients were analyzed in two groups, one with standard LLT, and the other with LLT plus LA. Over and above reductions in LDL-C levels achieved with background LLT; lomitapide reduced LDL-C levels by 56.8% and 54% in these groups, respectively, at an average dose of 21.4 ± 10.5 mg/day [44].

An interesting case history has been recently published of two Spanish brothers with HoFH and poor response to standard LLTs [45]. One of the brothers had renal failure (two transplants), and a range of concomitant medications would have made him ineligible for a clinical trial. The patient had also undergone a triple coronary bypass. The other brother was more straightforward but had also undergone a triple bypass. Both brothers were receiving apheresis at the time lomitapide was initiated. LDL-C levels reduced to < 100 mg/dL in both patients, and the first brother was able to stop LA [45*].

Not all patients can benefit from low doses of lomitapide. It is known that there can be variability in response to the drug [46], and it is possible that this is driven by phenotypic variability in MTP. This notion is borne out by data from a study of four HoFH cases from Greece treated with lomitapide in which two patients were characterized as “hyper-responders” (LDL-C reductions > 50%) and two as “hypo-responders” (LDL-C reductions < 50%). Genetic analysis revealed 36 different mutations in MTP, among which the two hyper-responders shared six common gene variants. None of these variants was present in the hypo-responders [47]. An example of hypo-respondiveness was evident in a 2015 case from a Hispanic female [48]. Raper et al. continued to treat a HoFH patient who had been on the maximum 60 mg/day dose of lomitapide in the pivotal phase 3 trial. Attempts were made to reduce the dose to 40 mg/day, but the patient experienced rebound in LDL-C characteristic of hypo-respondiveness. However, the success in this patient lies in that she was able to achieve LDL-C levels of just 50 mg/dL with discontinuation of LA and only a transient increase in LFTs at the time of the re-escalation in lomitapide dose [48].

Despite the need to diagnose and treat HoFH as early as possible in life, at the time of writing, lomitapide does not have a license in pediatric patients. However, a case series has been published in which 11 HoFH patients all < 18 years old (mean age 11.6 ± 1.1 years) were treated with lomitapide in accordance with the adult label, albeit with smaller starting doses (2.5 mg/day) [16]. The patients were split between 10 centers in eight countries, so there was variability in practice patterns, availability of LA and reimbursement policies [16]. Addition of lomitapide to standard background LLT resulted in a mean decrease in LDL-C of 58.4 ± 6.8%. Six of the patients achieved EAS pediatric LDL-C target levels < 135 mg/dL. Among the six patients who were receiving LA, all of them had their LA frequency reduced, and three were able to stop LA altogether. One patient, who was on a twice-weekly LA schedule, was able to reduce his LA burden by 75%.

| Pt | Lomitapide Start, year | Lomitapide dose | LA start, year | Baseline liver US, year | Baseline steatosis | Last US, year | Steatosis on last US | Baseline MRI, year | Baseline Steatosis on MRI | Last MRI, year | Steatosis on last MRI |
|----|------------------------|----------------|---------------|-------------------------|-------------------|---------------|---------------------|-------------------|------------------------|---------------|----------------------|
| 1  | 2010                   | 5–60 mg/day    | 1990          | NA                      | NA                | NA            | NA                  | 2010              | None                   | 2018          | Diffuse               |
| 2  | 2015                   | 5–30 mg/day    | 1996          | 2015                    | Slight            | 2019          | Slight              | 2016              | Slight                 | NA            | NA                   |
| 3  | 2014                   | 5–30 mg/day    | 2003          | 2015                    | None              | 2019          | None                | 2016              | Slight                 | 2019          | None                 |
| 4  | 2015                   | 5–25 mg/day    | 2004          | 2015                    | None              | 2018          | Slight              | 2015              | None                   | 2018          | Slight               |
| 5  | 2014                   | 5–30 mg/day    | 1996          | 2014                    | None              | 2019          | None                | N/A               | N/A                    | N/A           | N/A                  |
| 6  | 2014*                  | 5–20 mg/day    | 1993          | 2015                    | None              | Nov 2017      | (regression)        | 2016              | None                   | N/A           | N/A                  |
| 7  | 2015*                  | 5–15 mg/day    | 2011          | 2015                    | None              | 2016          | None                | May               | NA                     | N/A           | N/A                  |
| 8  | 2019*                  | 5 mg/day       | 1989          | 2010                    | None              | August 2019   | Mild                | 2019              | April                  | N/A           | N/A                  |
| 9  | 2019                   | 5 mg/day       | 2000          | January 2019            | None              | October 2019  | Slight              | N/A               | N/A                    | N/A           | N/A                  |

LA lipoprotein apheresis, MRI magnetic resonance imaging, N/A not applicable, US ultrasound

*Lomitapide discontinued at date indicated

Table 2  Hepatic steatosis data from 9 HoFH patients treated with lomitapide in Rome (unpublished data)
Adverse events were similar to other studies with a predominance of manageable GI disturbances and transient LLT excursions [16].

An earlier single-patient case study was reported of a 7-year-old girl with HoFH who was treated with lomitapide for 4 years [49]. The care team used the same principles of therapy as for adult patients (fat restriction, background statins and essential fatty acids, and vitamin E supplementation). The patient achieved a 37% reduction in LDL-C down to a nadir of 232 mg/dL with lomitapide 20 mg/day and no LA [49].

In Greece, an 8-year-old boy with HoFH and extensive xanthomas, with systolic murmur in both carotid arteries and aortic valve stenosis, was treated unsuccessfully with statins, in a setting where LA was not an option due to issues of both venous access and parental consent [50]. LDL-C levels were very high at 1050 mg/dL, and the statin regimen was only able to get this down to 866 mg/dL. Treatment with lomitapide escalated to 40 mg/day resulted in LDL-C levels reaching 390 mg/dL. There was notable regression of xanthomas, and no side effects were reported [50]. In this case, lomitapide resulted in considerable LDL-C reduction, but still insufficient to protect the patient against long-term evolution of atherosclerosis and related cardiovascular complications, and the patient remained on combination LLT therapy.

LOWER is beginning to yield evaluable data on the long-term effects of lomitapide in a large number of patients. As of March 2017, 163 patients were enrolled in the registry, and Larrey et al. conducted an analysis of longitudinal liver safety with 47.1 months mean exposure to lomitapide [51]. Mean lomitapide dose was 10 mg/day. Larrey et al. confirmed that LFT excursions are common in patients receiving lomitapide but that the magnitude of these is a lot less than in the phase 3 trial, with only 6.3% of patients experiencing transaminase levels > 5× upper limit of normal over 3 years in LOWER versus 9% in the 28-week clinical trial [51]. Hepatic abnormalities have been recorded for approximately 15% of patients in the registry. The use of imaging to determine hepatic steatosis/fibrosis is patchy but will be available from the European cohort because imaging or biomarker-based assessment of hepatic parameters is mandatory in Europe [52]. No patient in LOWER has satisfied the criteria for Hy’s Law [51].

The totality of the currently available RWE on lomitapide strongly indicates when the drug is used without the forced

![Fig. 2](image-url)  
**Fig. 2** Hepatic MRI for patient 3 in a 2015 and b 2018 (unpublished data)

![Fig. 3](image-url)  
**Fig. 3** Hepatic ultrasound for patient 5 in a 2014 and b 2019 (unpublished data)
maximum tolerated dose (MTD) titration that characterized the pivotal phase 3 trial; most patients and care teams find that the drug can be used at lower doses than the median trial dose and therefore with fewer side effects. Lomitapide can allow for increases in LA intervals and, in a minority of patients, even cessation of the procedure, providing that mean interval LDL-C and Lp(a) levels are under control and there is no evidence of progression of ASCVD.

**CV Outcomes for Lomitapide**

As described above, there are insufficient patients with HoFH to generate data on cardiovascular event rates and survival. Nonetheless, researchers have made attempts to estimate the possible benefits of lomitapide on CV events by conducting modelling analyses based on existing data. In a modelling analysis by Leipold et al., an assumption was made on the basis of the phase 3 pivotal trial of lomitapide in HoFH that the drug was capable of eliciting a conservative 38% reduction in LDL-C levels [53]. Using an historical study of mortality the drug was capable of eliciting a conservative 38% reduction in LDL-C levels [54]. It was possible to calculate age-dependent hazards and treatment-dependent hazard ratios for mortality and time to first major adverse cardiovascular events (MACE). It was estimated that for every millimoles per liter of LDL-C reduction, the relative risk of mortality decreased by 23%, and the risk of a major adverse cardiovascular event reduced by 15%. Importantly, using the same data, the mean life expectancy was estimated to increase by 5.7 years if lomitapide was commenced at age 18 years and by 6.7 years if the drug was commenced at birth [53].

A further modelling analysis has been conducted using data derived from the phase 3 pivotal trial of lomitapide. In this instance, CV event rates were estimated along with the proportion of patients achieving EAS guideline targets of \( \leq \) 100 mg/dL and \( \leq \) 70 mg/dL. These data were compared with additional data derived from clinical trials of evolocumab and mipomersen [55]. The lomitapide analysis used data from all 29 patients enrolled in the phase 3 study. Over the first 26 weeks of the phase 3 trials, 15 patients reached the \( \leq \) 100 mg/dL LDL-C target at least once, and eight (28%) reached the \( \leq \) 70 mg/dL target. In the extension study, 19 patient remained on lomitapide, and of these, 14 (74%) reached the \( \leq \) 100 mg/dL LDL-C target at least once, and 11 (58%) reached the \( \leq \) 70 mg/dL target [55]. Only two MACE were reported in the lomitapide trial, which equates to 1.7 events per 1000 patient months of treatment. Corresponding rates for mipomersen and evolocumab were 9.5 and 1.8, respectively. On-treatment LDL-C levels for lomitapide, mipomersen, and evolocumab were estimated to be 166, 331, and 286 mg/dL, respectively [55]. Additional data on CV endpoints may become available on evolocumab and lomitapide, but mipomersen has been discontinued by the manufacturer, and no further information will be available on this drug.

These results together with those of Leipold et al. support the notion that lomitapide has the potential to reduce CV event rates in the general population of HoFH patients receiving the drug, which may have important benefits in terms of reducing the burden of treating CV events.

**Conclusions**

HoFH is a rare, genetic disorder of lipid metabolism that causes extremely elevated high LDL-C levels from birth, resulting in severe and aggressive CVD at a very early age. HoFH is an extremely difficult to treat disease that requires multiple therapeutic interventions in the pursuit of target LDL-C levels and to control levels of Lp(a). Recent registry data have become available from HICC and A-HIT which emphasize the ongoing high CV risk of HoFH and the impact of HoFH on Quality of life despite the availability of lipid lowering therapies such as statins and apheresis, highlighting the need for additional therapeutic options.

On the basis of a phase 3 clinical trial, lomitapide was licensed for use as an adjunct to low-fat diet and lipid lowering therapies, including apheresis, in adult patients with HoFH. Lomitapide has been available for long enough now for many physicians to have used it in patients outside of clinical trials. When the drug is used without the forced MTD titration in the phase 3, most care teams are finding that the drug can be used at lower doses than the median trial dose and therefore with fewer side effects. Despite the lower median dose, the LDL-C lowering effect is equivalent or greater than that observed in the clinical studies with the majority of patients achieving LDL-C target levels.

Lomitapide can enable adjustment of LA schedules to reduce therapeutic burden. In a minority of HoFH patients, a complete cessation of LA can be achieved, provided that target LDL-C (estimated by the calculation of mean LDL-C interval between LA sessions) is achieved and that cardiovascular imaging of coronary arteries and aortic valve is reported to be stable. However, the coexistence of elevated Lp(a) levels may contraindicate cessation of LA as elevated Lp(a) has been associated with increased mortality in HoFH [18••]. Careful serial monitoring of the liver by means of liver imaging is essential.

Recent modelling data demonstrate that, in the absence of outcomes data, there is a potential benefit of lomitapide in terms of life years gained, decrease in time to major adverse CV events, and EAS target attainment. This has the potential not only to improve survival but also to avoid treatment of the costly sequelae of clinically significant CVD.
Acknowledgments Professor Stefanutti would like to thank Nigel Eastmond of Eastmond Medicom Ltd. for assistance in preparing the manuscript. Professor Stefanutti would like to thank Dr. Dario Mesce, Radiology Technician, for his careful review of US and NMR scans, serially performed in our patients, and Serafina Di Giacomo, MD PhD, and Claudia Morozzi, MD, for their careful review of the patients’ clinical records.

Funding Information This work was funded by Amryt Pharmaceuticals DAC, which is the manufacturer of lomitapide.

Compliance and Ethical Standards

Conflict of Interest Professor Stefanutti has no current, relevant conflicts of interest to report.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and no permission indicated to be permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
• Of major importance

1. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146–57. https://doi.org/10.1093/eurheartj/ehu274.

2. Representatives of the Global Familial Hypercholesterolemia C, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. 2020. doi:https://doi.org/10.1001/jamacardio.2019.5173.

3. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90. https://doi.org/10.1093/eurheartj/eht273.

4. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36(3):560–5. https://doi.org/10.1093/eurheartj/ehu058.

5. Al-Ashwal A, Alnouri F, Sabbour H, Al-Mahfouz A, Al-Sayed N, Razzaghy-Azar M, et al. Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East Advisory Panel. Curr Vasc Pharmacol. 2015;13(6):759–70.

6. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262–8. https://doi.org/10.1016/j.atherosclerosis.2012.02.019.

7. Hartgers M, Cuchel M, Hovingh GK, Blom DJ, Raal FJ. Clinical, demographic and genetic characteristics of homozygous familial hypercholesterolemia patients worldwide: Interim results from the hoFH international clinical collaborators (HICC) registry. Atherosclerosis. 2018;275:e60. https://doi.org/10.1016/j.atherosclerosis.2018.06.022 Recent international registry data on HoFH.

8. Kaycioglu M, Tokgozoglu L, Yilmaz M, Kaynar L, Aktan M, Durmus RB, et al. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). Atherosclerosis. 2018;270:42–8. Turkish HoFH registry data of patients on LA. https://doi.org/10.1016/j.atherosclerosis.2018.01.034.

9. Staneu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–87. https://doi.org/10.1111/j.1582-4934.2001.tb00172.x.

10. Krahnenbuhl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won’t do! Drugs. 2016;76(12):1175–90. https://doi.org/10.1007/s40265-016-0613-0.

11. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102(9):1199–204. https://doi.org/10.1016/j.amjcard.2008.06.049.

12. Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015;17(1):465. https://doi.org/10.1007/s11883-014-0465-6.

13. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2):317–21. https://doi.org/10.1016/j.atherosclerosis.2009.06.010.

14. Kroon AA, van’t Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152(2):519–26. https://doi.org/10.1016/S0021-9150(00)00371-3.

15. Thompson GR, Catapano A, Saheb S, Attassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21(6):492–8. https://doi.org/10.1097/MOL.0b013e3283402f53.

16. Ben-Omran T, Masana L, Kolovou G, Arcieta G, Novoa FJ, Lund AM, et al. Real-world outcomes with Lomitapide use in paediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786–811. https://doi.org/10.1007/s12325-019-00985-8.

17. Bruckert E, Saheb S, Bonté JR, Courdary-Ommès C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey. Atheroscler Suppl. 2014;15:46–51.

18. Stefanutti C, Pang J, Di Giacomo S, Wu X, Wang X, Morozzi C, et al. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman Study. Journal of Clinical Lipidology. 2019;13(4):608–17. https://
38. Garcia CK, Wilkund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292(5520):1394–8. https://doi.org/10.1126/science.1060458.

39. Garuti R, Jones C, Li WP, Michaela P, Herz J, Gerard RD, et al. The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem. 2005;280(49):40996–1004. https://doi.org/10.1074/jbc.M509394200.

40. Sanchez-Hernandez RM, Prieto-Matos P, Civeira F, Lafuente EE, Vargas MF, Real JT, et al. Autosomal recessive hypercholesterolemia in Spain. Atherosclerosis. 2018;269:1–5. https://doi.org/10.1016/j.atherosclerosis.2017.12.006.

41. Stefanutti C, Morozzi C, Di Giacomo S, Sovrano B, Mesce D, Cesaro A, et al. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. J Am Coll Cardiol. 2019;7(3):279–288. doi: https://doi.org/10.1016/j.jacc.2017.11.028.

42. Garcia CK, Wilkund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292(5520):1394–8. https://doi.org/10.1126/science.1060458.

43. Garuti R, Jones C, Li WP, Michaela P, Herz J, Gerard RD, et al. The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem. 2005;280(49):40996–1004. https://doi.org/10.1074/jbc.M509394200.

44. Sanchez-Hernandez RM, Prieto-Matos P, Civeira F, Lafuente EE, Vargas MF, Real JT, et al. Autosomal recessive hypercholesterolemia in Spain. Atherosclerosis. 2018;269:1–5. https://doi.org/10.1016/j.atherosclerosis.2017.12.006.

45. Stefanutti C, Morozzi C, Di Giacomo S, Sovrano B, Mesce D, Cesaro A, et al. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. J Am Coll Cardiol. 2019;7(3):279–288. doi: https://doi.org/10.1016/j.jacc.2017.11.028.

46. Garcia CK, Wilkund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292(5520):1394–8. https://doi.org/10.1126/science.1060458.

47. Garuti R, Jones C, Li WP, Michaela P, Herz J, Gerard RD, et al. The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem. 2005;280(49):40996–1004. https://doi.org/10.1074/jbc.M509394200.

48. Sanchez-Hernandez RM, Prieto-Matos P, Civeira F, Lafuente EE, Vargas MF, Real JT, et al. Autosomal recessive hypercholesterolemia in Spain. Atherosclerosis. 2018;269:1–5. https://doi.org/10.1016/j.atherosclerosis.2017.12.006.

49. Stefanutti C, Morozzi C, Di Giacomo S, Sovrano B, Mesce D, Grossi A. Management of homozygous familial hypercholesterolemia in real-world clinical practice: a report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. Journal of clinical lipidology. 2016;10(4):782–9. https://doi.org/10.1016/j.jacl.2016.02.009.

50. Sperlongano S, Gragnano F, Natale F, D’Erasmo L, Concilio C, Cesaro A, et al. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. J Cardiovasc Med (Hagerstown). 2018;19(3):83–90. https://doi.org/10.2459/JCM.0000000000000620.

51. Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: experiences with lomitapide. Journal of clinical lipidology. 2015;9(4):607–17. https://doi.org/10.1016/j.jacl.2015.05.001.

52. Kolovou G, Dikoumakou O, Kolovou V, Fountas E, Stratakis S, Zacharis E, et al. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolemia. Eur J Prev Cardiol. 2020;27(2):157–65. https://doi.org/10.1177/2047487319870007.

53. Real J, Arbona C, Gotteris R, Aascaso JF. Management of homozygous familial hypercholesterolemia in two brothers. BMJ Case Rep. 2018;2018. https://doi.org/10.1136/bcr-2017-222155 An
interesting case series that highlights the heterogeneity of management in HoFH.

46. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019;14:19–30. https://doi.org/10.2147/CE.S174169.

47. Kolovou GD, Kolovou V, Papadopoulou A, Watts GF. MTP gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2016;23(7): 878–83. https://doi.org/10.5551/jat.34777.

48. Raper A, Kolansky DM, Sachais BS, Meagher EA, Baer AL, Cuchel M. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. Journal of clinical lipidology. 2015;9(1): 107–12. https://doi.org/10.1016/j.jacl.2014.08.005.

49. Chacra APM, Ferrari MC, Rocha VZ, Santos RD. Case report: the efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child. Journal of clinical lipidology. 2019;13(3): 397–401. https://doi.org/10.1016/j.jacl.2019.03.001.

50. Kolovou G, Tsoutsinos A, Mastorakou I, Mavrogeni S, Hatzigeorgiou G. Xanthomas regression in an 8-year-old boy treated with lomitapide. JACC Case Reports. 2019;1(3):414–6. https://doi.org/10.1016/j.jaccs.2019.06.029.

51. Larrey D, Underberg J, Cannon C, Makris L, Jurecka A, Blom D. Long-term liver safety of lomitapide in patients with homozygous familial hypercholesterolemia: three-year data from the lomitapide observational worldwide evaluation registry (LOWER). J Hepatol. 2018;68(Suppl. 1):S588. The most recent published dataset from the long-term lomitapide registry.

52. Amryt Pharmaceuticals DAC. Lojuxta summary of product characteristics. 2017.

53. Leipold R, Raal F, Ishak J, Hovingh K, Phillips H. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: a modelling analysis. Eur J Prev Cardiol. 2017;24(17):1843–50. https://doi.org/10.1177/2047487317730473.

54. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202–7. https://doi.org/10.1161/CIRCULATIONAHA.111.042523.

55. Blom DJ, Cuchel M, Ager M, Phillips H. Target achievement and cardiovascular event rates with Lomitapide in homozygous familial hypercholesterolaemia. Orphanet J Rare Dis. 2018;13(1):96. https://doi.org/10.1186/s13023-018-0841-3.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.